AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24726095
Drug: Raltegravir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 800 mg twice daily
Trial: 24726095
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg once daily plus tenofovir and lamivudine
Trial: 10780154
Drug: Client-centered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered group psychotherapy (twice a week, approximately 100 sessions)
Trial: 10780154
Drug: Clinical standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical standard treatment (control group)
Trial: 1306004
Drug: Heparin-glucuronylglucosaminoglycane combination
RxNorm normalized name: heparin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-glucuronylglucosaminoglycane combination
Trial: 29380190
Drug: Automated closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated closed-loop goal-directed fluid therapy
Trial: 29380190
Drug: Manual fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual fluid administration (control)
Trial: 27399350
Drug: Nω‐hydroxy‐nor‐L‐arginine (arginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nω‐hydroxy‐nor‐L‐arginine (arginase inhibitor)
Trial: 20397499
Drug: Groups E,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups E, F, G, and H (same post-and-core materials as Groups A-D without TSC)
Trial: 18234424
Drug: G‐CSF (Filgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (Filgrastim) 5 mcg/kg/day
Trial: 18234424
Drug: G‐CSF (Filgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (Filgrastim) 10 mcg/kg/day
Trial: 18234424
Drug: Dose-intensified AC
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensified AC followed by T
Trial: 11223696
Drug: alpha(1)‐Adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha(1)‐Adrenoceptor antagonists such as tamsulosin
Trial: 11223696
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with alpha-blockers
Trial: 11223696
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with alpha-blockers
Trial: 9137507
Drug: D‐galactose (1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐galactose (1.9 g/kg BW per day)
Trial: 9137476
Drug: D‐glucose‐containing electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐glucose‐containing electrolyte infusions
Trial: 31888699
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) administered to the motor cortex (M1) or dorso lateral prefrontal cortex (DLPFC) for 10 sessions over 4 weeks at 2 mA for 20 minutes.
Trial: 31888699
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group receiving no active tDCS treatment.
Trial: 28844214
Drug: Chamomile ointment
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile ointment
Trial: 23429642
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily for 5 days
Trial: 23429642
Drug: Boceprevir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir 800 mg three times daily for 5 days
Trial: 23429642
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily + Boceprevir 800 mg three times daily for 5 days
Trial: 16729287
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg MRA/kg body weight
Trial: 15616416
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) for 4 weeks
Trial: 11207873
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modulators
Trial: 15064089
Drug: Androgen replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen replacement therapy
Trial: 9218932
Drug: Coca-Cola (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coca-Cola (325 ml) with 100 mg itraconazole
Trial: 9218932
Drug: Water (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (325 ml) with 100 mg itraconazole
Trial: 3478276
Drug: Intra-cervical 15-Me
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-cervical 15-Me PGF2 alpha gel
Trial: 6586395
Drug: Intracervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2 gel
Trial: 3478276
Drug: Intra-cervical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-cervical gel alone (placebo)
Trial: 16989163
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Hymenoptera venom
Trial: 4616806
Drug: Chlormethiazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole (500 mg in 10 ml dose)
Trial: 4616806
Drug: Nitrazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam (10 mg single dose)
Trial: 4616806
Drug: Overall assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall assessment of treatment
Trial: 31419313
Drug: Standard treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment: 18 months of teriparatide followed by 18 months of denosumab
Trial: 31419313
Drug: Cyclic treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment: three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab
Trial: 31419313
Drug: Cyclic treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment
Trial: 30583667
Drug: Consultation based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consultation based on Health Belief Model (4 weekly sessions)
Trial: 26700457
Drug: saline (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (0.9 mL)
Trial: 26700457
Drug: capsaicin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsaicin (3 mg in 0.2 mL saline with 7% Tween 80)
Trial: 26700457
Drug: morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (10 mg kg(‐1))
Trial: 26700457
Drug: butorphanol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: butorphanol (10 mg kg(‐1))
Trial: 17493108
Drug: Nicotine lozenges
RxNorm normalized name: nicotine Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine lozenges
Trial: 12786834
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% fusidic acid plus 0.1% betamethasone cream
Trial: 12786834
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% mupirocin and 0.1% betamethasone cream
Trial: 11198658
Drug: Mefloquine 25
RxNorm normalized name: mefloquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 25 mg base/kg plus artesunate 4 mg/kg per day for 3 days (MAS3)
Trial: 11198658
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg salt/kg every 8 h) for 7 days (Q7)
Trial: 9384466
Drug: Ro 48-8684
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-8684 (0.1-0.3-1 mg and 1-3-10 mg doses)
Trial: 9384466
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg(‐1) kg)
Trial: 9384466
Drug: Ro 48-8684
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-8684 (10 mg)
Trial: 9384466
Drug: Ro 48-8684
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-8684 (doses increasing from 1 to 10 mg)
Trial: 25982391
Drug: Hop tablets
RxNorm normalized name: HOPS
DrugBank: Hops (DB10687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hop tablets for 12 weeks
Trial: 25982391
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 12 weeks
Trial: 24456059
Drug: Environmental enrichment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Environmental enrichment (EE) for 2 hours daily starting 24 hours post-injury
Trial: 24456059
Drug: Simvastatin (Sim)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (Sim) for 2 hours daily starting 24 hours post-injury
Trial: 16042674
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 mg day(‐1))
Trial: 16042674
Drug: Valsartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (40 mg day(‐1))
Trial: 8175622
Drug: half-dose T+K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half-dose T+K (T/2 + K group)
Trial: 2953870
Drug: Zoladex (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (sustained-release luteinizing hormone-releasing hormone analogue) administered by subcutaneous injection every 28 days
Trial: 2383925
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of 50 mU of biosynthetic human growth hormone (b‐hGH)
Trial: 2383925
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of somatostatin (1‐14)
Trial: 2383925
Drug: Infusions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of exogenous hormone (3 mU/kg/h) for 15, 30, 60 and 180 min
Trial: 796740
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron 1-2 g every 4 months
Trial: 796740
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron plus testosterone
Trial: 796740
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron and androgens
Trial: 23641902
Drug: Campath (alemtuzumab)-based
RxNorm normalized name: alemtuzumab Injection [Campath]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath (alemtuzumab)-based induction therapy
Trial: 23641902
Drug: Sirolimus-based maintenance
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus-based maintenance therapy
Trial: 23641902
Drug: Basiliximab-based therapy
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab-based therapy
Trial: 19345060
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention including standard treatment, supervised exercise program (4-6 weeks, 1 hour/day, 5 days/week), progressive relaxation, and psychoeducation.
Trial: 19345060
Drug: Standard treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment, care, and physiotherapy (control group).
Trial: 11305517
Drug: New fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New fecal calprotectin method with a cut-off limit of 50 microg/g
Trial: 11305517
Drug: Original fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original fecal calprotectin method with a cut-off limit of 10 mg/l
Trial: 11305517
Drug: New fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New fecal calprotectin method with a cut-off limit of 150 microg/g
Trial: 2973777
Drug: Enoximone (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (low doses ≤ 1 mg/kg) in group A (n = 11)
Trial: 2973777
Drug: Enoximone (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (high doses > 1 mg/kg) in group B (n = 12)
Trial: 24610603
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine gel (10 ml)
Trial: 24610603
Drug: Liquid paraffin
RxNorm normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid paraffin (10 ml)
Trial: 21778294
Drug: Morphine (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.07 mg/kg)
Trial: 17020434
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs
Trial: 11553427
Drug: Adjunct questions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct questions (AQ)
Trial: 9863075
Drug: TCM‐WM therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM‐WM therapy (DMSA and Gandou decoction for 1 month)
Trial: 9863075
Drug: WM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM therapy (DMSA only)
Trial: 30506558
Drug: Carbetocin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 20 μg
Trial: 31599627
Drug: Duluth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duluth treatment program
Trial: 31247165
Drug: Psychomotor Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor Therapy (PMT) in combination with Active Exercise (AE) for 12 weeks
Trial: 28279704
Drug: Pharmaceutical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical placebo
Trial: 19371313
Drug: sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil 100 mg + sublingual GTN 400 microg
Trial: 19371313
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + sublingual GTN 400 microg
Trial: 16791814
Drug: External radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External radiation therapy targeted on the neck and upper mediastinum
Trial: 16791814
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of newly formed lymph node metastases
Trial: 24016557
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment results
Trial: 10695915
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 1)
Trial: 10695915
Drug: Cortisol infusion
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 2)
Trial: 10695915
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (group 3)
Trial: 10695915
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (group 4)
Trial: 9180060
Drug: Conventional pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional pharmaceutical therapy (primarily amiodarone)
Trial: 29514234
Drug: Enhanced prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced prophylaxis (cotrimoxazole plus 12 weeks of isoniazid + fluconazole, single-dose albendazole, and 5 days of azithromycin)
Trial: 23959817
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (intratympanic methylprednisolone + oral steroid)
Trial: 23959817
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid alone
Trial: 19180895
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% methylene blue (MB) hydrogel with photodynamic therapy (PDT) using 565 mW LED 670 nm light
Trial: 19180895
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% methylene blue (MB) hydrogel
Trial: 19180895
Drug: Histopathological examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histopathological examination post-treatment
Trial: 17923598
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (mean dose 1.3 ± 0.4 mg/kg)
Trial: 15318852
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ASA 12 hours before apheresis (Group A)
Trial: 15318852
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication before donation (Group B)
Trial: 11831838
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg once daily
Trial: 9848591
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac supplemented by oral oxycodone
Trial: 9848591
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine via patient‐controlled analgesia (PCA) device
Trial: 10890259
Drug: Cefdinir 300
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 300 mg BID
Trial: 9589816
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg QID
Trial: 1884609
Drug: Polyclonal immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal immunoglobulin preparation (n = 27)
Trial: 31699029
Drug: Intravenous loop
RxNorm normalized name: LOOP OSTOMY ROD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous loop diuretics (LDs)
Trial: 23895672
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (angioplasty or stenting)
Trial: 22440436
Drug: Interactive computer‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive computer‐based tool (CatInfo) containing a detailed audiovisual presentation about cataract and its treatment
Trial: 18769351
Drug: darunavir/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/r 800/100 mg once daily
Trial: 18769351
Drug: darunavir/r 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/r 600/100 mg twice daily
Trial: 12388173
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate weekly (group 1)
Trial: 9659025
Drug: mivacurium 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.04 mg.kg‐1
Trial: 9659025
Drug: mivacurium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.08 mg.kg‐1
Trial: 8521310
Drug: propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 2.5 mg.kg‐1
Trial: 8070508
Drug: Oral Cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cyclosporin (CsA) solution (mean daily dose: 23.3 mg.kg‐1) in CF subjects
Trial: 8070508
Drug: Oral Cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cyclosporin (CsA) solution in non-CF subjects (mean daily dose: 4.8 mg.kg‐1)
Trial: 2904313
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (0.25 to 8 micrograms min‐1 kg‐1)
Trial: 2904313
Drug: Metoclopramide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide infusion
Trial: 17543392
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment
Trial: 14508327
Drug: Acetazolamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (5 mg/kg)
Trial: 9037361
Drug: Filgrastim 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 1.0 microgram/kg s.c. daily for 3‐7 days followed by CEOP with filgrastim support 10 micrograms/kg s.c. daily, day 2‐14
Trial: 9037361
Drug: CEOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP chemotherapy (C 500 mg/m2, E 37.5 mg/m2, O 2 mg, P 75 mg/m2)
Trial: 9037361
Drug: CEOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEOP chemotherapy (C 750 mg/m2, E 50 mg/m2, O 2 mg, P 75 mg/m2)
Trial: 1577056
Drug: Theophylline 5
RxNorm normalized name: theophylline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 5 mg.kg-1 per day with omeprazole 20 mg per day
Trial: 1577056
Drug: Theophylline 5
RxNorm normalized name: theophylline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 5 mg.kg-1 per day with placebo
Trial: 3000412
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus ACNU (100 mg/m2 on day 1 and 42)
Trial: 3000412
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus ACNU and tegafur (400 mg/m2, daily for 8 weeks)